Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Cash from Investing Activities (2020 - 2023)

Candel Therapeutics' Cash from Investing Activities history spans 4 years, with the latest figure at -$27000.0 for Q4 2023.

  • For Q4 2023, Cash from Investing Activities rose 90.22% year-over-year to -$27000.0; the TTM value through Dec 2023 reached -$280000.0, up 78.41%, while the annual FY2024 figure was -$16000.0, 94.29% up from the prior year.
  • Cash from Investing Activities for Q4 2023 was -$27000.0 at Candel Therapeutics, up from -$103000.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $20.2 million in Q4 2020 and bottomed at -$732000.0 in Q3 2020.
  • The 4-year median for Cash from Investing Activities is -$222000.0 (2021), against an average of $1.1 million.
  • The largest annual shift saw Cash from Investing Activities crashed 102.5% in 2021 before it surged 111.11% in 2023.
  • A 4-year view of Cash from Investing Activities shows it stood at $20.2 million in 2020, then plummeted by 102.5% to -$504000.0 in 2021, then skyrocketed by 45.24% to -$276000.0 in 2022, then surged by 90.22% to -$27000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Cash from Investing Activities are -$27000.0 (Q4 2023), -$103000.0 (Q3 2023), and -$169000.0 (Q2 2023).